Michael Yee
Stock Analyst at UBS
(3.94)
# 595
Out of 5,239 analysts
117
Total ratings
46.99%
Success rate
12.95%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Buy | $75 → $100 | $62.94 | +58.88% | 4 | Apr 28, 2026 | |
| BIIB Biogen | Upgrades: Buy | $185 → $225 | $200.64 | +12.14% | 7 | Apr 22, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $90 → $60 | $61.47 | -2.39% | 3 | Apr 21, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $45 | $18.92 | +137.84% | 1 | Apr 21, 2026 | |
| AMGN Amgen | Maintains: Buy | $390 → $400 | $332.21 | +20.41% | 8 | Apr 13, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $130 → $145 | $112.68 | +28.69% | 1 | Apr 13, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $27 | $25.87 | +4.37% | 2 | Apr 13, 2026 | |
| KOD Kodiak Sciences | Maintains: Buy | $50 → $80 | $38.90 | +105.66% | 5 | Mar 27, 2026 | |
| SDGR Schrödinger | Maintains: Neutral | $18 → $13 | $12.80 | +1.56% | 4 | Mar 17, 2026 | |
| NUVB Nuvation Bio | Maintains: Neutral | $10 → $7 | $4.79 | +46.29% | 5 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $230 | $206.12 | +11.59% | 2 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $535 → $545 | $449.05 | +21.37% | 6 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $155 | $133.09 | +16.47% | 5 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $50 | $28.40 | +76.06% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $25 | $19.65 | +27.23% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $24 → $55 | $29.07 | +89.20% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $5.63 | +113.14% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $16.55 | +202.11% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $49.52 | +21.18% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.75 | +86.67% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $13.32 | +237.84% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $37.35 | +60.64% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $32.10 | -12.77% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.30 | +247.83% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.51 | +79.40% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.53 | +206.51% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $56.19 | +15.68% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $1,000.92 | +24.89% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $2.05 | +46.34% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $50.80 | +8.27% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $369.50 | +4.19% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.19 | -42.20% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $14.92 | +34.05% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.14 | +856.94% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.34 | +221.20% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $31.50 | +280.95% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $112.13 | -73.25% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $29.32 | +162.62% | 2 | Nov 8, 2018 |
Oruka Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $75 → $100
Current: $62.94
Upside: +58.88%
Biogen
Apr 22, 2026
Upgrades: Buy
Price Target: $185 → $225
Current: $200.64
Upside: +12.14%
AnaptysBio
Apr 21, 2026
Maintains: Buy
Price Target: $90 → $60
Current: $61.47
Upside: -2.39%
First Tracks Biotherapeutics
Apr 21, 2026
Initiates: Buy
Price Target: $45
Current: $18.92
Upside: +137.84%
Amgen
Apr 13, 2026
Maintains: Buy
Price Target: $390 → $400
Current: $332.21
Upside: +20.41%
Merck & Co.
Apr 13, 2026
Maintains: Buy
Price Target: $130 → $145
Current: $112.68
Upside: +28.69%
Pfizer
Apr 13, 2026
Maintains: Neutral
Price Target: $25 → $27
Current: $25.87
Upside: +4.37%
Kodiak Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $50 → $80
Current: $38.90
Upside: +105.66%
Schrödinger
Mar 17, 2026
Maintains: Neutral
Price Target: $18 → $13
Current: $12.80
Upside: +1.56%
Nuvation Bio
Mar 3, 2026
Maintains: Neutral
Price Target: $10 → $7
Current: $4.79
Upside: +46.29%
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $206.12
Upside: +11.59%
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $449.05
Upside: +21.37%
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $133.09
Upside: +16.47%
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $28.40
Upside: +76.06%
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $19.65
Upside: +27.23%
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $29.07
Upside: +89.20%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $5.63
Upside: +113.14%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $16.55
Upside: +202.11%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $49.52
Upside: +21.18%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $3.75
Upside: +86.67%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $13.32
Upside: +237.84%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $37.35
Upside: +60.64%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $32.10
Upside: -12.77%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.30
Upside: +247.83%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $19.51
Upside: +79.40%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $6.53
Upside: +206.51%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $56.19
Upside: +15.68%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $1,000.92
Upside: +24.89%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.05
Upside: +46.34%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $50.80
Upside: +8.27%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $369.50
Upside: +4.19%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.19
Upside: -42.20%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $14.92
Upside: +34.05%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.14
Upside: +856.94%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.34
Upside: +221.20%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $31.50
Upside: +280.95%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $112.13
Upside: -73.25%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $29.32
Upside: +162.62%